Literature DB >> 9808587

Oxidative modification of low-density lipoprotein and atherogenetic risk in beta-thalassemia.

M A Livrea1, L Tesoriere, A Maggio, D D'Arpa, A M Pintaudi, E Pedone.   

Abstract

We investigated the oxidative state of low-density lipoprotein (LDL) in patients with beta-thalassemia to determine whether there was an association with atherogenesis. Conjugated diene lipid hydroperoxides (CD) and the level of major lipid antioxidants in LDL, as well as modified LDL protein, were evaluated in 35 beta-thalassemia intermedia patients, aged 10 to 60, and compared with age-matched healthy controls. Vitamin E and beta-carotene levels in LDL from patients were 45% and 24% of that observed in healthy controls, respectively. In contrast, the mean amount of LDL-CD was threefold higher and lysil residues of apo B-100 were decreased by 17%. LDL-CD in thalassemia patients showed a strong inverse correlation with LDL vitamin E (r = -0.784; P <.0001), while a negative trend was observed with LDL-beta-carotene (r = -0.443; P =.149). In the plasma of thalassemia patients, malondialdehyde (MDA), a byproduct of lipid peroxidation, was increased by about twofold, while vitamin E showed a 52% decrease versus healthy controls. LDL-CD were inversely correlated with plasma vitamin E (r = -0.659; P <.0001) and correlated positively with plasma MDA (r = 0.621; P <. 0001). Plasma ferritin was positively correlated with LDL-CD (r = 0.583; P =.0002). No correlation was found between the age of the patients and plasma MDA or LDL-CD. The LDL from thalassemia patients was cytotoxic to cultured human fibroblasts and cytotoxicity increased with the content of lipid peroxidation products. Clinical evidence of mild to severe vascular complications in nine of the patients was then matched with levels of LDL-CD, which were 36% to 118% higher than the mean levels of the patients. Our results could account for the incidence of atherogenic vascular diseases often reported in beta-thalassemia patients. We suggest that the level of plasma MDA in beta-thalassemia patients may represent a sensitive index of the oxidative status of LDL in vivo and of its potential atherogenicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808587

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Oxidative modification and poor protective activity of HDL on LDL oxidation in thalassemia.

Authors:  Supeenun Unchern; Narumon Laohareungpanya; Yupin Sanvarinda; Kovit Pattanapanyasat; Pansakorn Tanratana; Udom Chantharaksri; Nathawut Sibmooh
Journal:  Lipids       Date:  2010-06-09       Impact factor: 1.880

2.  Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.

Authors:  Patrick B Walter; Ellen B Fung; David W Killilea; Qing Jiang; Mark Hudes; Jacqueline Madden; John Porter; Patricia Evans; Elliott Vichinsky; Paul Harmatz
Journal:  Br J Haematol       Date:  2006-10       Impact factor: 6.998

3.  Association between apolipoprotein ε4 allele, factor V Leiden, and plasma lipid and lipoprotein levels with sickle cell disease in Southern Iran.

Authors:  Zohreh Rahimi; Asad Vaisi-Raygani; Tayebeh Pourmotabbed
Journal:  Mol Biol Rep       Date:  2010-04-07       Impact factor: 2.316

4.  Prolidase activity and oxidative status in patients with thalassemia major.

Authors:  Alpay Cakmak; Murat Soker; Ahmet Koc; Nurten Aksoy
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

5.  Pseudoxanthoma elasticum: oxidative stress and antioxidant diet in a mouse model (Abcc6-/-).

Authors:  Qiaoli Li; Qiujie Jiang; Jouni Uitto
Journal:  J Invest Dermatol       Date:  2007-11-29       Impact factor: 8.551

Review 6.  Atherogenesis and iron: from epidemiology to cellular level.

Authors:  Francesca Vinchi; Martina U Muckenthaler; Milene C Da Silva; György Balla; József Balla; Viktória Jeney
Journal:  Front Pharmacol       Date:  2014-05-05       Impact factor: 5.810

7.  Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker.

Authors:  Laila M Sherief; Osama Dawood; Adel Ali; Hanan S Sherbiny; Naglaa M Kamal; Mohamed Elshanshory; Osama Abd Alazez; Mohamed Abd Alhady; Mohamed Nour; Wesam A Mokhtar
Journal:  BMC Pediatr       Date:  2017-03-09       Impact factor: 2.125

8.  Assessment of Myocardial Performance Index and Aortic Elasticity in Patients With Beta-Thalassemia Major.

Authors:  Cem Sahin; Ozcan Basaran; Ibrahim Altun; Fatih Akin; Yasar Topal; Hatice Topal; Murat Biteker; Mehmet Fatih Azik
Journal:  J Clin Med Res       Date:  2015-08-23

9.  Nutritional biomarkers in children and adolescents with Beta-thalassemia-major: An Egyptian center experience.

Authors:  Laila M Sherief; Sanaa M Abd El-Salam; Naglaa M Kamal; Osama El Safy; Mohamed A A Almalky; Seham F Azab; Hemat M Morsy; Amal F Gharieb
Journal:  Biomed Res Int       Date:  2014-04-08       Impact factor: 3.411

10.  Impact of Genetic Polymorphism of methylenetetrahydrofolate reductase C677T on Development of Hyperhomocysteinemia and Related Oxidative Changes in Egyptian β-Thalassemia Major Patients.

Authors:  Mai A Abd-Elmawla; Sherine M Rizk; Ilham Youssry; Amira A Shaheen
Journal:  PLoS One       Date:  2016-05-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.